Actively Recruiting
National Longitudinal Cohort of Hematological Diseases - Autoimmune Hemolytic Anemia
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-06-17
9999
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating autoimmune hemolytic anemia (AIHA), a disorder affecting the blood and blood-forming organs. This study aims to understand the incidence and risk factors of AIHA in China and to analyze treatment effectiveness, patient outcomes, and healthcare costs. It addresses the need for a comprehensive, large-scale prospective cohort study in hematology, as previous cohorts have been limited in size or scope. The study involves a combined retrospective and prospective observational follow-up approach. Researchers will collect detailed patient information from medical records, including diagnosis, treatment, and healthcare costs. Questionnaires will be used to gather patient exposure data, while ongoing follow-up will capture prognosis information over time. Participants diagnosed with AIHA will be tracked at various points, with hematologic response assessed at baseline, 6 months, 12 months, 24 months after treatment, and at study completion. The study will also evaluate relapse rates, mortality, long-term prognosis, and quality of life. Data collection focuses on demographic and clinical features, treatment patterns, and real-world outcomes.
CONDITIONS
Brief Title
National Longitudinal Cohort of Hematological Diseases- Autoimmune Hemolytic Anemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with autoimmune hemolytic anemia (AIHA)
- Hemoglobin level less than 100 g/L
- Treated at the Institute of Hematology and Blood Diseases Hospital from January 1, 2001 onward
You will not qualify if you...
- Unlikely to be available for long-term follow-up due to inability to provide follow-up data or severe other illnesses
- Alcohol or drug dependence that may reduce study compliance
- Other reasons determined by the investigator that make the participant unsuitable for the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 24 months and beyond
Participants are observed over time with assessments including hematologic response and prognosis information collected.
Visits at baseline, 6 months, 12 months, and 24 months, with additional assessments approximately yearly
Trial Site Locations
Total: 1 location
1
Red Blood Cell Diseases Center and Regenerative Medicine Center
Tianjin, Tianjin Municipality, China
Actively Recruiting
Research Team
L
Lele Zhang, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here